Quantity of eligible patients: CDEC discussed the uncertainty in the number of people with reasonably critical to critical hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people that are categorized as getting moderate or reasonable condition may have a intense bleeding https://hemgenix49304.blogsuperapp.com/36418073/about-hemgenix